{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:12:38Z","timestamp":1795115558344,"version":"4.10.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>People affected by rare diseases want to be involved in research and the search for new treatments. Randomized controlled trials remain the best way of finding new interventions, but many elements of traditional study design are not best suited for rare diseases. Barriers to patients and families include the use of specialist hospital sites for recruitment, requiring frequent site-based study visits for data collection, and a high burden of tests and outcome measures in research. While decentralized clinical trial (DCT) designs have been developed in some rare disease trials, changes necessitated by the COVID-19 pandemic present an opportunity for them to become a standard approach. DCT approaches have been shown to be more resilient to changes in enrolment and attrition during COVID-19 than traditional designs and offer benefits in terms of patient burden, convenience, inclusion, and data quality. Digital tools such as wearable devices and electronic clinical outcome assessments may also provide more convenient and environmentally valid measures of how a condition affects the life of an individual in their regular environment (e.g. mobility around the home versus a hospital corridor). Digital solutions have greater ability to support language localization, accessibility, and may lead to increase access to global rare disease trials. In parallel, challenges exist, such as the technical support, the digital divide, ensuring high quality data, and delivering safe trials.<\/jats:p>","DOI":"10.1186\/s13023-022-02388-5","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T11:09:04Z","timestamp":1655723344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["What role can decentralized trial designs play to improve rare disease studies?"],"prefix":"10.1186","volume":"17","author":[{"given":"J.","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1376-1541","authenticated-orcid":false,"given":"N.","family":"Goodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Reites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165\u201373.","journal-title":"Eur J Hum Genet"},{"key":"2388_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","volume":"178","author":"TJ Moore","year":"2018","unstructured":"Moore TJ, Zhang H, Anderson G, Alexander GC. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015\u20132016. JAMA Intern Med. 2018;178:1451.","journal-title":"JAMA Intern Med"},{"key":"2388_CR3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajmg.a.61124","volume":"179","author":"CR Ferreira","year":"2019","unstructured":"Ferreira CR. The burden of rare diseases. Am J Med Genet. 2019;179:885\u201392.","journal-title":"Am J Med Genet"},{"key":"2388_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10897-013-9642-y","volume":"23","author":"SJ DeWard","year":"2014","unstructured":"DeWard SJ, Wilson A, Bausell H, Volz AS, Mooney K. Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience. J Genet Counsel. 2014;23:20\u20138.","journal-title":"J Genet Counsel"},{"key":"2388_CR5","unstructured":"NORD Rare Insights. Barriers to rare disease diagnosis, care and treatment in the US: a 30-year comparative analysis. National Organization for Rare Disorders. 2020. https:\/\/rarediseases.org\/wp-content\/uploads\/2020\/11\/NRD-2088-Barriers-30-Yr-Survey-Report_FNL-2.pdf."},{"key":"2388_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41746-022-00603-y","volume":"5","author":"N Goodson","year":"2022","unstructured":"Goodson N, Wicks P, Morgan J, Hashem L, Callinan S, Reites J. Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion. NPJ Digit Med. 2022;5:58.","journal-title":"NPJ Digit Med"},{"key":"2388_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12913-017-2090-x","volume":"17","author":"P DasMahapatra","year":"2017","unstructured":"DasMahapatra P, Raja P, Gilbert J, Wicks P. Clinical trials from the patient perspective: survey in an online patient community. BMC Health Serv Res. 2017;17:166.","journal-title":"BMC Health Serv Res"},{"key":"2388_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-021-01734-3","volume":"16","author":"C Chaplin","year":"2021","unstructured":"Chaplin C. Unmasked: an insight into three patients\u2019 rare disease experiences during the COVID-19 pandemic. Orphanet J Rare Dis. 2021;16:88.","journal-title":"Orphanet J Rare Dis"},{"key":"2388_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.medj.2021.04.010","volume":"2","author":"KP Vasisht","year":"2021","unstructured":"Vasisht KP, Nugent BM, Woodcock J. Progress and opportunities for women in clinical trials: a look at recent data and initiatives from the U.S. FDA. Med. 2021;2:456\u20139.","journal-title":"Med"},{"key":"2388_CR10","doi-asserted-by":"publisher","first-page":"g6802","DOI":"10.1136\/bmj.g6802","volume":"349","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Thompson L, O\u2019Keefe K, Kesselheim AS. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802\u2013g6802.","journal-title":"BMJ"},{"key":"2388_CR11","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.nmd.2021.07.145","volume":"31","author":"O Anyanwu","year":"2021","unstructured":"Anyanwu O, Stoodley M, Davies E, Lewi D, George E, Bull D, et al. EP.120 Industry and patient advocacy led co-development of a novel digital endpoint for Duchenne muscular dystrophy. Neuromuscul Disord. 2021;31:S85.","journal-title":"Neuromuscul Disord"},{"key":"2388_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13:61.","journal-title":"Orphanet J Rare Dis"},{"key":"2388_CR13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/ana.25892","volume":"88","author":"ER Dorsey","year":"2020","unstructured":"Dorsey ER, Kluger B, Lipset CH. The new normal in clinical trials: decentralized studies. Ann Neurol. 2020;88:863\u20136.","journal-title":"Ann Neurol"},{"key":"2388_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/978-3-319-67144-4_34","volume-title":"Rare diseases epidemiology: update and overview","author":"SC Groft","year":"2017","unstructured":"Groft SC, Posada de la Paz M. Preparing for the future of rare diseases. In: Posada de la Paz M, Taruscio D, Groft SC, editors. Rare diseases epidemiology: update and overview. Cham: Springer; 2017. p. 641\u20138."},{"key":"2388_CR15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/s13063-021-05457-5","volume":"22","author":"S van Koningsbruggen-Rietschel","year":"2021","unstructured":"van Koningsbruggen-Rietschel S, Dunlevy F, Bulteel V, Hayes K, Verbrugge A, Janssens HM, et al. Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures. Trials. 2021;22:578.","journal-title":"Trials"},{"key":"2388_CR16","unstructured":"Parent Project Muscular Dystrophy. The Duchenne registry celebrates one year of data collection in our smartphone app!. Parent Project Muscula Dystrophy. 2020 [cited 2022 Jan 28]. https:\/\/www.parentprojectmd.org\/the-duchenne-registry-celebrates-one-year-of-data-collection-in-our-smartphone-app\/."},{"key":"2388_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13023-021-01766-9","volume":"16","author":"CCY Chung","year":"2021","unstructured":"Chung CCY, Ng YNC, Jain R, Chung BHY. A thematic study: impact of COVID-19 pandemic on rare disease organisations and patients across ten jurisdictions in the Asia Pacific region. Orphanet J Rare Dis. 2021;16:119.","journal-title":"Orphanet J Rare Dis"},{"key":"2388_CR18","unstructured":"FDA Oncology Center of Excellence. Advancing oncology decentralized trials: learning from COVID-19 trial datasets [Internet]. US Food and Drug Administration. 2021 [cited 2022 Feb 16]. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/advancing-oncology-decentralized-trials."},{"key":"2388_CR19","volume":"91","author":"MM Shirke","year":"2020","unstructured":"Shirke MM, Shaikh SA, Harky A. Implications of telemedicine in oncology during the COVID-19 pandemic. Acta Bio Med Atenei Parm. 2020;91: e2020022.","journal-title":"Acta Bio Med Atenei Parm"},{"key":"2388_CR20","doi-asserted-by":"crossref","unstructured":"Sirintrapun SJ, Lopez AM. Telemedicine in cancer care. American Society of Clinical Oncology Educational Book. 2018. p. 540\u2013545.","DOI":"10.1200\/EDBK_200141"},{"key":"2388_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2217\/cer-2020-0143","volume":"9","author":"FD Mowlem","year":"2020","unstructured":"Mowlem FD, Sanderson B, Platko JV, Byrom B. Optimizing electronic capture of patient-reported outcome measures in oncology clinical trials: lessons learned from a qualitative study. J Comp Eff Res. 2020;9:1195\u2013204.","journal-title":"J Comp Eff Res"},{"key":"2388_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11764-020-00942-3","volume":"15","author":"CL Riis","year":"2021","unstructured":"Riis CL, Stie M, Bechmann T, Jensen PT, Coulter A, M\u00f6ller S, et al. ePRO-based individual follow-up care for women treated for early breast cancer: impact on service use and workflows. J Cancer Surviv. 2021;15:485\u201396.","journal-title":"J Cancer Surviv"},{"key":"2388_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s43441-021-00278-9","volume":"55","author":"F McErlane","year":"2021","unstructured":"McErlane F, Davies EH, Ollivier C, Mayhew A, Anyanwu O, Harbottle V, et al. Wearable technologies for children with chronic illnesses: an exploratory approach. Ther Innov Regul Sci. 2021;55:799\u2013806.","journal-title":"Ther Innov Regul Sci"},{"key":"2388_CR24","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1161\/STROKEAHA.118.023779","volume":"50","author":"J Walsh","year":"2019","unstructured":"Walsh J, Markus HS. Telemedicine for follow-up of rare neurological disease: development and evaluation in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2019;50:750\u20133.","journal-title":"Stroke"},{"key":"2388_CR25","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1212\/WNL.0b013e3182377e29","volume":"77","author":"J Cialone","year":"2011","unstructured":"Cialone J, Augustine EF, Newhouse N, Vierhile A, Marshall FJ, Mink JW. Quantitative telemedicine ratings in batten disease: implications for rare disease research. Neurology. 2011;77:1808\u201311.","journal-title":"Neurology"},{"key":"2388_CR26","unstructured":"IQVIA Institute. Orphan drugs in the United States: rare disease innovation and cost trends through 2019 [Internet]. IQVIA Institute; 2020. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/orphan-drugs-in-the-united-states-rare-disease-innovation-and-cost-trends-through-2019."},{"key":"2388_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13023-018-0936-x","volume":"13","author":"P Kaufmann","year":"2018","unstructured":"Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases\u2014the view from the National Center for Advancing Translational Sciences\u2014Office of Rare Diseases Research. Orphanet J Rare Dis. 2018;13:196.","journal-title":"Orphanet J Rare Dis"},{"key":"2388_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13023-016-0532-x","volume":"11","author":"W Davies","year":"2016","unstructured":"Davies W. Insights into rare diseases from social media surveys. Orphanet J Rare Dis. 2016;11:151.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02388-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02388-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T11:14:48Z","timestamp":1655723688000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02388-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02388-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors JM, NG, and JR are employees of THREAD research. PW is employed by Wicks Digital Health Ltd, which has received funding from Ada Health, AstraZeneca, Baillie Gifford, Biogen, Bold Health, Camoni, Compass Pathways, Coronna, EIT, Endava, Happify, HealthUnlocked, Inbeeo, Kheiron Medical, Lindus Health, MedRhythms, Sano Genetics, Self Care Catalysts, The Learning Corp, The Wellcome Trust, THREAD Research, VeraSci, and Woebot.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}